Mora Raimundo, PatriciaLozano Borregón, DanielManzano García, MiguelVallet Regí, María Dulce Nombre2023-06-172023-06-172019-05-091936-085110.1021/acsnano.9b00241https://hdl.handle.net/20.500.14352/13303RESEARCHER ID B-5081-2017 (Daniel Lozano Borregón) ORCID 0000-0001-5902-9201 (Daniel Lozano Borregón) RESEARCHER ID K-3719-2014 (Miguel Manzano García) ORCID 0000-0001-6238-6111 (Miguel Manzano García) RESEARCHER ID M-3378-2014 (María Vallet Regí) ORCID 0000-0002-6104-4889 (María Vallet Regí)Osteoporosis is the most common disease involving bone degeneration. Current clinical treatments are not able to offer a satisfying curative effect, so the development of effective treatments is desired. Gene silencing through siRNA delivery has gained great attention as a potential treatment in bone diseases. SOST gene inhibits the Wnt signaling pathway reducing osteoblast differentiation. Consequently, silencing SOST gene with a specific siRNA could be a potential option to treat osteoporosis. Generally, siRNAs have very short half-life and poor transfection capacity, so an effective carrier is needed. In particular, mesoporous silica nanoparticles (MSNs) have attracted great attention for intracellular delivery of nucleic acids. We took advantage of their high loading capacity to further load the pores with osteostatin, an osteogenic peptide. In this study we developed a system based on MSNs coated with poly(ethylenimine), which can effectively deliver SOST siRNA and osteostatin inside cells, with the consequent augmentation of osteogenic markers with a synergistic effect. This established the potential utility of MSNs to co-deliver both biomolecules to promote bone formation, being a potential alternative to treat osteoporosis.engAtribución-NoComercial 3.0 Españajournal articlehttps://pubs.acs.org/http://www.ucm.es/valletregigroupopen access615.46546Mesoporous nanoparticlesGene silencingOsteoporosisTherapeutic co-deliveryOsteogenic stimulationMaterialesQuímica inorgánica (Farmacia)3312 Tecnología de Materiales